Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bilastine effects on F1 simulator driving performance in patients with allergic rhinitis and/or urticaria
2015-001313-26Phase 4Completed
- Sponsor
- Menarini Group
- Start
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of bilastine in allergic rhinitis (AR) and urticaria, sponsored by Menarini Group. Primary endpoint: Standard deviation of lateral position. Started Jul 2016; status: completed.
02
Drugs
bilastine
03
Conditions
allergic rhinitis (AR)urticaria
Beyond the preview
Go deeper on 2015-001313-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001313-26.